Federica Di Nicolantonio Selected Research

Panitumumab (Vectibix)

12/2016	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.
2/2016	MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.
1/2016	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.
7/2015	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
12/2014	TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells.
11/2014	Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.
9/2014	Acquired resistance to EGFR-targeted therapies in colorectal cancer.
2/2014	Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.
6/2012	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
7/2011	Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Federica Di Nicolantonio Research Topics

Disease

74	Neoplasms (Cancer) 02/2022 - 04/2002
62	Colorectal Neoplasms (Colorectal Cancer) 02/2022 - 05/2005
7	Disease Progression 05/2021 - 05/2012
7	Colonic Neoplasms (Colon Cancer) 01/2021 - 01/2012
7	Carcinoma (Carcinomatosis) 03/2015 - 07/2003
7	Ovarian Neoplasms (Ovarian Cancer) 09/2006 - 07/2002
6	Melanoma (Melanoma, Malignant) 01/2021 - 01/2003
6	Neoplasm Metastasis (Metastasis) 01/2018 - 01/2003
4	Sarcoma (Soft Tissue Sarcoma) 04/2016 - 11/2004
3	Breast Neoplasms (Breast Cancer) 01/2018 - 12/2004
3	Adenocarcinoma 03/2015 - 06/2003
2	Lung Neoplasms (Lung Cancer) 01/2021 - 09/2014
2	Microsatellite Instability 01/2021 - 01/2017
2	Pancreatic Neoplasms (Pancreatic Cancer) 08/2017 - 10/2011
2	Stomach Neoplasms (Stomach Cancer) 12/2016 - 07/2003
2	Uveal melanoma 07/2006 - 11/2004
1	Turcot syndrome 01/2022
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 05/2021
1	Malignant Mesothelioma 05/2021
1	Drug-Related Side Effects and Adverse Reactions 01/2021
1	Carcinogenesis 10/2020
1	Osteosarcoma (Osteogenic Sarcoma) 06/2020
1	Glioblastoma (Glioblastoma Multiforme) 01/2019
1	Circulating Neoplastic Cells 01/2018
1	Adenoma (Adenomas) 01/2018
1	Mucinous Adenocarcinoma (Mucinous Carcinoma) 01/2017

Drug/Important Bio-Agent (IBA)

22	Cetuximab (Erbitux)FDA Link 03/2020 - 05/2005
20	ErbB Receptors (EGF Receptor)IBA 03/2020 - 05/2005
16	Panitumumab (Vectibix)FDA Link 12/2016 - 05/2005
15	Pharmaceutical PreparationsIBA 05/2021 - 04/2002
13	Monoclonal AntibodiesIBA 12/2016 - 05/2005
12	Adenosine Triphosphate (ATP)IBA 01/2017 - 07/2002
9	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2009
9	DNA (Deoxyribonucleic Acid)IBA 12/2020 - 04/2002
7	Proteins (Proteins, Gene)FDA Link 12/2019 - 01/2006
6	Doxorubicin (Adriamycin)FDA LinkGeneric 06/2020 - 07/2002
6	Calcibiotic Root Canal SealerIBA 01/2019 - 02/2014
6	AntibodiesIBA 02/2016 - 11/2011
6	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 09/2014 - 05/2012
5	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 01/2017
5	Cell-Free Nucleic AcidsIBA 12/2020 - 08/2013
5	Fluorouracil (Carac)FDA LinkGeneric 01/2020 - 07/2002
5	Phosphotransferases (Kinase)IBA 01/2018 - 01/2006
5	Cisplatin (Platino)FDA LinkGeneric 07/2005 - 07/2002
4	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2019
4	Circulating Tumor DNAIBA 01/2021 - 07/2015
4	Biological ProductsIBA 07/2017 - 06/2013
4	Paclitaxel (Taxol)FDA LinkGeneric 07/2005 - 01/2003
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2017 - 02/2015
3	PLX 4720IBA 01/2017 - 02/2012
3	Small Interfering RNA (siRNA)IBA 04/2016 - 04/2014
3	Vinorelbine (Navelbine)FDA LinkGeneric 10/2004 - 07/2002
2	Bevacizumab (Avastin)FDA Link 02/2022 - 08/2017
2	DNA-Directed DNA Polymerase (Polymerases, DNA)IBA 01/2022 - 04/2002
2	Ascorbic Acid (Vitamin C)FDA LinkGeneric 03/2020 - 01/2020
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020 - 04/2014
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2020 - 11/2004
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 07/2005
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2020 - 01/2019
2	EnzymesIBA 01/2019 - 03/2015
2	VemurafenibIBA 01/2016 - 01/2012
2	Codon (Codons)IBA 02/2015 - 10/2010
2	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 04/2014 - 07/2006
2	Oncogene Proteins (Oncogene Protein)IBA 01/2012 - 11/2011
2	Gefitinib (Iressa)FDA Link 01/2012 - 11/2004
2	Mitogen-Activated Protein KinasesIBA 10/2011 - 03/2007
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 05/2006 - 06/2005
2	Epirubicin (Ellence)FDA LinkGeneric 07/2005 - 07/2003
2	Antineoplastic Agents (Antineoplastics)IBA 07/2005 - 01/2003
2	Gemcitabine FDA Link 11/2004 - 04/2002
2	treosulfanIBA 11/2004 - 07/2002
1	pembrolizumabIBA 01/2022
1	PM 01183IBA 05/2021
1	PlatinumIBA 05/2021
1	GTP Phosphohydrolases (GTPases)IBA 10/2020
1	Messenger RNA (mRNA)IBA 10/2020
1	MethyltransferasesIBA 01/2020
1	olaparibIBA 01/2020
1	Leucovorin (Folinic Acid)FDA Link 01/2020
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2020
1	sotorasibIBA 01/2020
1	Capecitabine (Xeloda)FDA Link 01/2020
1	GuanineIBA 01/2020
1	regorafenibIBA 01/2019
1	Neuropilin-1IBA 01/2018
1	bcl-X ProteinIBA 01/2018
1	LigandsIBA 08/2017
1	Angiopoietin-like ProteinsIBA 08/2017
1	Interleukin-8 (Interleukin 8)IBA 08/2017
1	Transcription Factors (Transcription Factor)IBA 08/2017
1	pevonedistatIBA 01/2017
1	Alkylating AgentsIBA 01/2017
1	Dacarbazine (DIC)FDA LinkGeneric 01/2017
1	Trastuzumab (Herceptin)FDA Link 12/2016
1	4- amino- 5- fluoro- 3- (5- (4- methylpiperazin- 1- yl)- 1H- benzimidazol- 2- yl)quinolin- 2(1H)- oneIBA 12/2016

Therapy/Procedure

52	Therapeutics 01/2022 - 04/2002
14	Drug Therapy (Chemotherapy) 05/2021 - 04/2002
3	Immunotherapy 01/2022 - 01/2020
1	Adjuvant Chemotherapy 01/2018
1	Time-to-Treatment 07/2017